Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Munich - Delayed Quote EUR

Compass Pathways PLC (5Y6.MU)

Compare

3.7000

+0.1000

+(2.78%)

As of 8:00:37 AM GMT+1. Market Open.

Compass one of the most compelling stories in neuropsych, says H.C. Wainwright

H.C. Wainwright tells investors in a research note that Compass Pathways (CMPS) is one of the most compelling stories in neuropsychiatry, and that COMP360’s differentiated profile positions it as a “transformative” treatment in treatment-resistant depression. The firm believes the current valuation fails to reflect the full scope of its opportunity across multiple large-market psychiatric disorders with COMP360 on track to become a blockbuster treatment, if approved. The firm reiterates a Buy ra

TipRanks 19 hours ago

CMPS
COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other psychedelic stocks. The Therapeutic Potential and Investment Boom in Psychedelic Medicine In contrast to drugs like cocaine or marijuana, psychedelics are […]

Insider Monkey 4 days ago

CMPS
Psychedelic: GH Research, Compass Pathways report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, an analyst initiation and patent issuance. EARNINGS: On Thursday, GH Research (GHRS) reported a FY24 loss per share of (75c), which compared to analyst estimates of loss per share of (80c). The company also reported cash, cash equivalents, other financial assets and marketable securities at $182.6M as of December 31, compared to cash, cash equivalents, other financial asset

TipRanks 5 days ago

QNTM

ENVB

CYBN
Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ...

Despite a significant net loss, Compass Pathways PLC (CMPS) secures financing to advance key clinical trials and strengthen its financial position.

GuruFocus.com 6 days ago

CMPS
Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript

CMPS earnings call for the period ending December 31, 2024.

Motley Fool 6 days ago

CMPS
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

LONDON & NEW YORK, February 27, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and full year 2024 and provided an update on recent progress across its business.

Business Wire 6 days ago

CMPS
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

LONDON & NEW YORK, February 25, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the TD Cowen 45th Annual Health Care Conference at 1:10 pm ET on March 3rd, 2025.

Business Wire 8 days ago

CMPS
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

LONDON & NEW YORK, February 18, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27th, 2025.

Business Wire 15 days ago

CMPS
It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

The Senate voted Thursday to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Investor's Business Daily 20 days ago

MNMD

MRNA

CMPS
Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

LONDON & NEW YORK, February 05, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference at 8:40 am ET on February 12th, 2025.

Business Wire 28 days ago

CMPS
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

LONDON & NEW YORK, January 21, 2025--Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by

Business Wire last month

CMPS
Compass Pathways Announces Pricing of Underwritten Offering

LONDON & NEW YORK, January 10, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares ("ADSs") and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant ("ADS Warrant") to purchase one

Business Wire last month

CMPS
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

LONDON, December 18, 2024--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 23, 2024.

Business Wire 2 months ago

CMPS
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

Don't jump in without doing some research first.

Motley Fool 3 months ago

CMPS
Compass Pathways to Participate in December Investor Conferences

LONDON & NEW YORK, November 25, 2024--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings:

Business Wire 3 months ago

CMPS
COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stake

Key Insights Institutions' substantial holdings in COMPASS Pathways implies that they have significant influence over...

Simply Wall St. 3 months ago

CMPS
Compass Pathways to participate in Stifel 2024 Healthcare Conference

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days

GlobeNewswire 3 months ago

CMPS
Compass Pathways cuts 30% of workforce on Phase 3 trial delays

Compass Pathways (CMPS) announced yesterday morning with earnings that as a result of changing timelines for its Phase 3 trials, it will be reducing its workforce by approximately 30%, including eliminating some senior management positions, “to further focus the organization and its capital resources on successfully delivering the COMP360 program.” The company’s non-COMP360 preclinical efforts will be stopped and it is “exploring a potential externalization” for its digital health tools. Publish

TipRanks 3 months ago

CMPS
Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Despite workforce reductions and trial delays, Compass Pathways PLC (CMPS) maintains a strong cash position and focuses on commercializing COMP360 for treatment-resistant depression.

GuruFocus.com 4 months ago

CMPS
Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript

CMPS earnings call for the period ending September 30, 2024.

Motley Fool 4 months ago

CMPS

Performance Overview

Return	5Y6.MU	MSCI WORLD
YTD	-4.15%	+1.91%
1-Year	-65.09%	+12.56%
3-Year	-69.55%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Compass Pathways PLC (5Y6.MU)

Compass one of the most compelling stories in neuropsych, says H.C. Wainwright

COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025

Psychedelic: GH Research, Compass Pathways report earnings results

Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ...

Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Compass Pathways Announces Pricing of Underwritten Offering

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

Compass Pathways to Participate in December Investor Conferences

COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stake

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways cuts 30% of workforce on Phase 3 trial delays

Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript

Performance Overview